ICON PLC Stock Euronext Dublin
Stocks
ICLR
IE0005711209
Biotechnology & Medical Research
| Market Cap | 12.73B 11.16B 10.31B 9.49B 17.9B 1,228B 18.18B 123B 48.34B 601B 47.8B 46.76B 2,069B | P/E 2026 * |
23.5x | P/E 2027 * | 19.3x |
|---|---|---|---|---|---|
| Enterprise Value | 15.12B 13.25B 12.25B 11.26B 21.25B 1,458B 21.59B 146B 57.4B 713B 56.76B 55.52B 2,457B | EV / Sales 2026 * |
1.88x | EV / Sales 2027 * | 1.73x |
| Free-Float |
99.56% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ICON PLC
| 1 day | -0.50% |
| Manager | Title | Age | Since |
|---|---|---|---|
Barry Balfe
CEO | Chief Executive Officer | 48 | 01/10/2025 |
Nigel Clerkin
DFI | Director of Finance/CFO | 53 | 01/10/2024 |
Ute Berger
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
John Climax
CHM | Chairman | 73 | 01/11/2002 |
Ciaran Murray
CHM | Chairman | 63 | 01/03/2017 |
Eugene McCague
BRD | Director/Board Member | 67 | 04/10/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.50% | -8.66% | - | - | 12.73B | |
| -0.49% | -4.01% | -0.84% | +2.28% | 48.71B | |
| -3.10% | -1.94% | +370.99% | +572.60% | 38.35B | |
| -0.46% | +2.18% | +5.44% | +61.01% | 34.53B | |
| -1.14% | -1.76% | +26.94% | -9.93% | 34.03B | |
| -1.82% | -1.43% | +0.52% | +31.85% | 26.77B | |
| -3.54% | -5.08% | - | - | 15.64B | |
| -1.82% | -0.43% | +69.28% | +113.82% | 15.08B | |
| +1.17% | +2.30% | +15.87% | +18.26% | 14.18B | |
| -0.92% | -1.67% | +1,270.07% | +629.01% | 11.61B | |
| Average | -1.26% | -1.32% | +219.78% | +177.36% | 26.54B | |
| Weighted average by Cap. | -1.31% | -1.53% | +140.32% | +152.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.06B 7.06B 6.53B 6B 11.33B 777B 11.51B 78.06B 30.6B 380B 30.26B 29.6B 1,310B | 8.31B 7.29B 6.74B 6.19B 11.69B 802B 11.88B 80.54B 31.57B 392B 31.22B 30.54B 1,351B |
| Net income | 520M 456M 421M 387M 731M 50.14B 743M 5.04B 1.97B 24.53B 1.95B 1.91B 84.52B | 608M 533M 493M 453M 855M 58.66B 869M 5.89B 2.31B 28.7B 2.28B 2.23B 98.88B |
| Net Debt | 2.39B 2.09B 1.93B 1.78B 3.35B 230B 3.41B 23.11B 9.06B 113B 8.96B 8.76B 388B | 1.66B 1.45B 1.34B 1.24B 2.33B 160B 2.37B 16.08B 6.3B 78.31B 6.23B 6.1B 270B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
